外周动脉疾病患者血脂管理效果:真实世界分析
基于MarketScan数据库2014-2018年250,103例外周动脉疾病(PAD)患者,评估降脂治疗(LLT)使用和实际 LDL-C 达标情况。结果显示高强度 LLT 使用率低(基线20.5%),40.0%未治疗;有 LDL-C 数据的患者中仅24.5%达标(<70 mg/dl),高强度治疗者中64%未达标。结论认为 PAD 患者血脂管理不充分,LLT 强度不能替代实际 LDL-C 达标。
要点
- PAD患者中40.0%未接受任何降脂治疗,高强度LLT仅占20.5%。
- 高强度LLT患者中64% LDL-C仍≥70 mg/dl,提示强度不能替代达标。
- 发生MACE或MALE后LLT使用和LDL-C达标率仍不理想。
核心结论
- PAD患者降脂治疗使用不足,LDL-C水平仍偏高,LLT强度是实际LDL-C达标情况的较差替代指标。
研究设计与样本
- 基于MarketScan数据库2014-2018年的回顾性队列研究,识别PAD患者250,103例。
主要发现
- 基线时20.5%接受高强度LLT,39.5%接受低强度LLT,40.0%未治疗;中位随访15个月,高强度LLT使用增加1.5%。
- 有LDL-C数据的18,747例患者中,基线时25.1%接受高强度LLT,中位LDL-C为91 mg/dl,24.5% LDL-C<70 mg/dl;高强度LLT亚组中位LDL-C为81 mg/dl,64% LDL-C≥70 mg/dl。
- 随访时高强度LLT使用增加3.7%,中位LDL-C降低4.0 mg/dl,LDL-C<70 mg/dl比例增加4.1%。
- 随访发生MACE后高强度LLT使用率为55.0%,MALE后为41.0%,无缺血事件为26.1%;MACE后LDL-C<70 mg/dl比例为41.5%,MALE后为36.1%,无事件为27.1%。
- 与随访LDL-C<70 mg/dl相关的因素包括吸烟、高血压、糖尿病、既往下肢血运重建和既往心肌梗死,但既往急性或危重肢体缺血未列入。
临床怎么用
- PAD患者应评估并启动降脂治疗,不应仅满足于使用高强度LLT,而应以LDL-C达标(<70 mg/dl)为目标。
- 发生MACE或MALE后应加强降脂治疗,但研究中事件后达标率仍有限,提示需优化治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Low-density lipoprotein cholesterol (LDL-C) is associated with heightened risk of major adverse cardiovascular events (MACE) and major adverse limb events (MALE) in peripheral artery disease (PAD). Lipid-lowering therapies (LLT) that reduce LDL-C decrease this risk. OBJECTIVES: The authors examined LLT use and actual achieved LDL-C in PAD. METHODS: PAD patients in MarketScan from 2014 to 2018 were identified. Outcomes included LLT use, defined as high-intensity (HI) (high-intensity statin, statin plus ezetimibe, or PCSK9 inhibitor), low-intensity (any other lipid regimen), or no therapy, and follow-up LDL-C. Factors associated with LDL-C <70 mg/dl were identified with multivariable logistic regression. RESULTS: Among 250,103 PAD patients, 20.5% and 39.5% were treated at baseline with HI and low-intensity LLT, respectively; 40.0% were on no LLT. Over a 15-month median follow-up period, HI LLT use increased by 1.5%. Among 18,747 patients with LDL-C data, at baseline, 25.1% were on HI LLT, median LDL-C was 91 mg/dl, and 24.5% had LDL-C <70 mg/dl. Within the HI LLT subgroup, median LDL-C was 81 mg/dl, and 64% had LDL-C ≥70 mg/dl. At follow-up, HI LLT use increased by 3.7%, median LDL-C decreased by 4.0 mg/dl, and an additional 4.1% of patients had LDL-C <70 mg/dl. HI LLT use was greater after follow-up MACE (55.0%) or MALE (41.0%) versus no ischemic event (26.1%). After MACE or MALE, LDL-C was <70 mg/dl in 41.5% and 36.1% of patients, respectively, versus 27.1% in those without an event. Factors associated with follow-up LDL-C <70 mg/dl included smoking, hypertension, diabetes, prior lower extremity revascularization, and prior myocardial infarction but not prior acute or critical limb ischemia. CONCLUSIONS: In PAD, LLT use is suboptimal, LDL-C remains elevated, and LLT intensity is a poor surrogate for achieved LDL-C. Less aggressive lipid management was observed in PAD versus cardiovascular disease, highlighting missed opportunities for implementation of proven therapies in PAD.
引用
- Hess CN, Cannon CP, Beckman JA, et al. Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2021. PMID: 34140105. doi:10.1016/j.jacc.2021.04.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。